BofA cuts target for Madrigal Pharmaceuticals stock to USD 533.00

Published on 10/27/2026 at 18:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Madrigal reports third-quarter results on November 3, 2026. Madrigal Pharmaceuticals stock costs EUR 394.95 on October 27, 2026 after hours in Europe.

Analyst target and reporting date

Bank of America Securities cut its Madrigal Pharmaceuticals target from USD 543.00 to USD 533.00 on October 19, 2026.
Madrigal Pharmaceuticals will release third-quarter 2026 results on November 3, 2026, before the U.S. market opens.
Madrigal Pharmaceuticals stock stood at EUR 394.95 at Lang & Schwarz on October 27, 2026 at 6:37 p.m. CEST.

MDGL, US5588681057, Illustration mit AI erstellt.

Madrigal Pharmaceuticals (ISIN US5588681057) faced a lower analyst valuation after Bank of America Securities cut its price target from USD 543.00 to USD 533.00 on October 19, 2026. Business Insider reported that analyst Jason Zemansky kept a Neutral rating. The stock stood at EUR 394.95 at Lang & Schwarz on October 27, 2026 at 6:37 p.m. CEST.

Target cuts meet a key trial date

The BofA target remains above the Nasdaq quote of USD 439.60 on October 27, 2026 at 1:41 p.m. ET, but the firm lowered its view by USD 10.00 from the earlier USD 543.00. The latest target change contrasts with UBS, which raised its target from USD 669.00 to USD 735.00 on October 14, 2026, according to Investing.com. UBS also lifted its stated F4 program success probability from 20.00 percent to 60.00 percent.

Revenue growth still meets losses

Madrigal reported USD 364.3 million in second-quarter 2026 revenue, up 71.00 percent from USD 212.8 million a year earlier. The company also posted a USD 57.9 million net loss and diluted loss of USD 1.99 per share for that quarter, according to Simply Wall St. The revenue increase therefore arrived alongside a wider earnings loss than the USD 1.90 loss per share reported for the second quarter of 2025.

November 3 is the next date

Madrigal will publish third-quarter 2026 financial results on November 3, 2026, before the U.S. market opens, and management will host a webcast at 8:00 a.m. ET. The company announced the date in an investor release on October 20, 2026 through its Madrigal Pharmaceuticals investor-relations site.

Madrigal had USD 292.7 million in cash and cash equivalents on June 30, 2026, while its market capitalization was USD 10.2 billion on October 27, 2026. The Nasdaq quote also placed the stock within a USD 393.61 to USD 615.00 52-week range, with 89,361 shares traded at the recorded time.

Analyst views remain divided

The competing targets show a wide valuation spread: USD 533.00 from Bank of America Securities versus USD 735.00 from UBS. For investors, the November report will provide the next quantified test of Rezdiffra sales growth and the companys path toward profitability.

Stock price and next catalyst

At Lang & Schwarz, Madrigal Pharmaceuticals stock stood at EUR 394.95 on October 27, 2026 at 6:37 p.m. CEST, after the Xetra session had ended. The Nasdaq quote was USD 439.60 on October 27, 2026 at 1:41 p.m. ET, while the next scheduled corporate event is the November 3, 2026 third-quarter report. The further course of trading is shown by the continuously updated real-time quote of Madrigal Pharmaceuticals stock.